The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has Arrived

HomeCirculationVol. 148, No. 14The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has Arrived No AccessArticle CommentaryRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessArticle CommentaryRequest AccessFull TextThe Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has Arrived Paul M Ridker Paul M RidkerPaul M Ridker Correspondence to: Paul M Ridker, MD, MPH, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, 900 Commonwealth Ave, Boston, MA 02215. Email E-mail Address: [email protected] https://orcid.org/0000-0003-1249-4522 Center for Cardiovascular Disease Prevention, Division of Preventive Medicine and the Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA. Originally published2 Oct 2023https://doi.org/10.1161/CIRCULATIONAHA.123.066510Circulation. 2023;148:1071–1073FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Sources of Funding and Disclosures, see page 1073.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Paul M Ridker, MD, MPH, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, 900 Commonwealth Ave, Boston, MA 02215. Email pridker@bwh.harvard.eduREFERENCES1. Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE; PROMINENT, REDUCE-IT, and STRENGTH Investigators. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomized trials.Lancet. 2023; 401:1293–1301. doi: 10.1016/S0140-6736(23)00215-5CrossrefMedlineGoogle Scholar2. Nelson K, Fuster V, Ridker PM. Low-dose colchicine for secondary prevention of coronary artery disease. JACC review topic of the week.J Am Coll Cardiol. 2023; 82:648–660. doi: 10.1016/j.jacc.2023.05.055CrossrefMedlineGoogle Scholar3. Opstal T, Fiolet A, van Broekhoven A, Mosterd A, Eikelboom JW, Nidorf SM, Thompson PL, Duyvendak M, van Eck JWM, van Beek EA, et al. Colchicine in patients with chronic coronary disease in relation to prior acute coronary syndrome.J Am Coll Cardiol. 2021; 78:859–866. doi: 10.1016/j.jacc.2021.06.037CrossrefMedlineGoogle Scholar4. Fiolet A, Opstal T, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, Kelly P, Tong DC, Layland J, Nidorf SM, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials.Eur Heart J. 2021; 42:2765–2775. doi: 10.1093/eurheartj/ehab115CrossrefMedlineGoogle Scholar5. Opstal T, Nidorf S, Fiolet A, Eikelboom JW, Mosterd A, Bax WA, Budgeon CA, Ronner E, Prins FJ, Tijssen JGP, et al. Drivers of mortality in patients with chronic coronary disease in the Low Dose Colchicine-2 trial.Int J Cardiol. 2023; 372:1–5. doi: 10.1016/j.ijcard.2022.12.026CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetails October 3, 2023Vol 148, Issue 14 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.123.066510PMID: 37782696 Originally publishedOctober 2, 2023 KeywordspreventioninflammationtreatmentatherosclerosisPDF download Advertisement SubjectsCardiovascular DiseaseClinical StudiesSecondary Prevention